218 related articles for article (PubMed ID: 30503324)
1. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
Cohen SE; Sachdev D; Lee SA; Scheer S; Bacon O; Chen MJ; Okochi H; Anderson PL; Kearney MF; Coffey S; Scott H; Grant RM; Havlir D; Gandhi M
Lancet HIV; 2018 Nov; ():. PubMed ID: 30503324
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
3. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
5. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
6. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
7. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
8. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
9. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
10. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
11. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
12. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
13. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
14. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
16. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
17. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
[TBL] [Abstract][Full Text] [Related]
18. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
[TBL] [Abstract][Full Text] [Related]
19. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]